

11-209-C100

Monoclonal Antibody to CD10 Purified Antibody (0.1 mg)

Clone: MEM-78

Isotype: Mouse IgG1

Specificity: The antibody MEM-78 reacts with CD10 antigen (CALLA - Common acute

lymphatic leukemia antigen), a 100 kDa type II integral membrane protein.

HLDA IV; WS Code B 506 HLDA V; WS Code B CD10.4

Regulatory Status: RUO

Immunogen: NALM-6 human pre-B cell line

Species Reactivity: Human

Application: Flow Cytometry

Recommended dilution:1 µg/ml

Immunoprecipitation

Purity: > 95% (by SDS-PAGE)

Purification: Purified by protein-A affinity chromatography

Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Storage / Stability: Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial

label.

Expiration: See vial label

Lot Number: See vial label

Background: CD10 (neutral endopeptidase – NEP, common acute lymphocytic leukemia

antigen – CALLA, membrane metallo-endopeptidase – MME, enkefalinase) is a 100-kDa cell surface zinc metalloprotease cleaving peptide bonds on the N-terminus of hydrophobic amino acids and inactivating multiple physiologically active peptids. CD10 is expressed on various normal cell types, including lymphoid precursor cells, germinal center B lymhocytes, and some epithelial cells, and its expression level serves as a marker for diagnostics of many carcinomas. CD10 is also a differentiation antigen for early B-lymphoid progenitors in the B-cell differentiation pathway and has a key role in regulation of growth,

differentiation and signal transduction of many cellular systems.



PRODUCT DATA SHEET

References:

*Suzuki T, Ino K, Kikkawa F, Uehara C, Kajiyama H, Shibata K, Mizutani S: Neutral endopeptidase/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway. Placenta. 2002 Jul;23(6):475-82.

*Yada K, Kashima K, Daa T, Kitano S, Fujiwara S, Yokoyama S: Expression of CD10 in basal cell carcinoma. Am J Dermatopathol. 2004 Dec;26(6):463-71.

*Braham H, Trimeche M, Ziadi S, Mestiri S, Mokni M, Amara K, Hachana M, Sriha B, Korbi S: CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch. 2006 Aug;449(2):220-4.

*Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY: Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Mar 2;7:3.

*Horejsi V, Angelisova P, Bazil V, Kristofova H, Stoyanov S, Stefanova I, Hausner P, Vosecky M, Hilgert I: Monoclonal antibodies against human leucocyte antigens. II. Antibodies against CD45 (T200), CD3 (T3), CD43, CD10 (CALLA), transferrin receptor (T9), a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74). Folia Biol (Praha). 1988;34(1):23-34. *Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989). *Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). *Angelisová P, Drbal K, Horejsí V, Cerný J: Association of CD10/neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol-anchored proteins and Lyn kinase. Blood. 1999 Feb 15;93(4):1437-9.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.